caa a22 4500 469121440 CHVBK 20180323133140.0 cr unu---uuuuu 170328e19920201xx s 000 0 eng 10.1007/BF02246250 doi (NATIONALLICENCE)springer-10.1007/BF02246250 Efficacy of moclobemide in different patient groups: a meta-analysis of studies [Elektronische Daten] [J. Angst, M. Stabl] Whilst tricyclic antidepressants are efficacious in all depressive syndromes, classical MAO-inhibitors differ substantially from them in their action. They are considered less effective in general and not very effective in endogenous depression, but recommended for the treatment of ‘atypical' depression. A new class of RIMA (Reversible Inhibitors of MAO-A) represented by moclobemide requires a change in clinical thinking on antidepressants. Moclobemide shows the same efficacy in depression as tricyclics: its effects are similar in unipolar and bipolar affective disorders, and in patients with major depressive episode superimposed on dysthymia (double depression). As with classical antidepressants, the response rate tends to be lower, but is still present in psychotic depression. Agitated depressives do not respond less well than non-agitated patients to moclobemide. Patients meeting DSM-III-R criteria for major depression with melancholia tend to respond better than non-melancholics, but this may be associated with the significantly higher baseline severity observed in melancholics. A slightly higher response rate in patients without concomitant benzodiazepine treatment, compared to those with benzodiazepine comedication, may also be related to baseline differences in the severity of depression. Elderly depressives respond less well than younger patients to classical antidepressants, but with moclobemide, elderly patients do as well as younger ones. Springer-Verlag, 1992 Moclobemide nationallicence Double-blind studies nationallicence Bipolar depression nationallicence Unipolar depression nationallicence Agitation nationallicence Retardation nationallicence Elderly nationallicence Benzodiazepines nationallicence Angst J. Research Department, Psychiatric University Hospital, P.O. Box 68, CH-8029, Zurich, Switzerland aut Stabl M. Clinical Research Neuropsychiatry, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut Psychopharmacology Springer-Verlag 106(1992-02-01), S109-S113 0033-3158 106<S109 1992 106 213 https://doi.org/10.1007/BF02246250 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02246250 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Angst J. Research Department, Psychiatric University Hospital, P.O. Box 68, CH-8029, Zurich, Switzerland aut NATIONALLICENCE 700 1- Stabl M. Clinical Research Neuropsychiatry, F. Hoffmann-La Roche Ltd, CH-4002, Basel, Switzerland aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106(1992-02-01), S109-S113 0033-3158 106<S109 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer